Any ideas anyone?

Interim Management Statement.

Highlights for the period
· Cogane™ demonstrated efficacy in a genetic preclinical model of amyotrophic lateral sclerosis (ALS).
· Dr Ian Tulloch, former Global Product Marketing Director at Novartis Pharma AG appointed as a Non-Executive Board Director. Dr Tulloch will succeed Mr Sandy Morrison who will step down as a Non-Executive Board Director following the Company's 2012 Annual General Meeting.
· Recruitment of patients with Parkinson's disease (PD) into the multi-national Cogane™ Phase II dose ranging study (CONFIDENT-PD) is ongoing.

Confirmatory data supports effectiveness of Cogane™ in
Amyotrophic Lateral Sclerosis

This time?

Interim Management Statement

Maybe this time?

preliminary Results

Business highlights

Operational

· Recruitment into CONFIDENT-PD Phase II clinical trial of Cogane™ in untreated patients with early stage Parkinson's disease was completed in April 2012 and the last patient is expected to complete the trial in late November 2012. Headline results from the trial remain on track to be available in February 2013.

· Cogane™ demonstrated efficacy in the "gold standard" preclinical model of amyotrophic lateral sclerosis ("ALS"), the most common form of motor neurone disease. Positive data have now been obtained in four models of ALS, providing a strong rationale for Cogane™ as a potential treatment for this devastating condition.

· A Phase I clinical trial to evaluate Cogane™ solid dose oral formulations for up to 28 days has been initiated.

· A study of Myogane™ in a preclinical model of glaucoma was inconclusive due to an unexpectedly low neuronal cell loss in the control group which prevented evaluation of a neuroprotective effect of Myogane™.

Corporate

· Dr Ian Tulloch was appointed as a non-executive Board director in February 2012. As planned, Mr Sandy Morrison stepped down from the Board following the Company's Annual General Meeting in March 2012.


Financial
· Loss after tax of £7.77 million in line with expectations reflects ongoing focus on the development of our pharmaceutical programmes (2011: £7.66 million).

· Cash and money market investments of £8.89 million (2011: £17.57 million). Based on our current expectations Phytopharm is financed to at least the end of Q1 2014.

Looks like the rumour mill is active.

Still quiet skinny,not even a mill traded so just mm playing games been watching all day.

Still have up tp 8 weeks or so before i jump on board......

Will get a new thread up and running soon as one to keep an eye on.

Coincidence?

COGANE™ IN ALS UPDATE

Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm", the "Group", or the "Company") today announces an update on plans for the further clinical development of CoganeTM as a potential treatment for Amyotrophic Lateral Sclerosis ("ALS").
Earlier this year the Company announced the successful completion of the preclinical evaluation of Cogane™ in ALS, which provided strong support for progression into clinical trials in this indication. Subsequently the Company has been working with a number of leading opinion leaders and charities with an interest in ALS to design a clinical development plan for Cogane™ in ALS.

As part of this process two leading grant-giving bodies, the ALS Association ("ALSA") and the North-East ALS Consortium ("NEALS") in conjunction with Massachusetts General Hospital, have provisionally indicated that they will provide financial and logistic support for future studies of Cogane™ in ALS. Both of these grants are contingent on the Company moving forward with a study in ALS.

The Company is also in discussion with leading regulatory agencies with regard to the design of a clinical development plan for Cogane™ in ALS.

Interim Management Statement

During the period

· The last patient completed participation in the CONFIDENT-PD Phase II clinical trial of Cogane™ in untreated patients with early-stage Parkinson's disease in December 2012. Results from this trial remain on track to be available in February 2013.

· Further work is ongoing with a number of leading opinion leaders and charities with an interest in Cogane™ in Amyotrophic Lateral Sclerosis ("ALS") to design a clinical development plan. Provisional indications for financial and logistical support for future studies of Cogane™ as a treatment for ALS have been received.

· A meeting has been held with the US Food and Drug Administration ("FDA") at which a clinical development plan for Cogane™ in ALS was agreed. Cogane™ for ALS has been granted Orphan Drug status which offers the potential for accelerated development compared with conventional drug development programs.

· A Phase I study of new solid dose formulations of Cogane™ was initiated and results are expected in Q1 2013.

· Our financial performance from 1 October 2012 to date continues to be in line with our expectations. Based on our current expectations Phytopharm is financed until at least the end of Q1 2014.

Last postings were a bit too optimistic . . and confused, some say - "...Despite the woeful sp, I'm thinking that maybe (only Maybe!) this is showing signs of potential.
EDIT. Ooops, sorry a lorry-load of chimps has taken over my keyboards...
EDIT 26March2012, AGM tomorrow, shan#t go as it's just too tedious welcoming new faces to the Board, who replace other faces that were welcomed a while back. Still this is buzzing about, waiting to land on the fly-paper one suspects . . . a long slow and painful future awaits..... all IMHO. Grr.

Todays failure of the Parkinson's Drug [ RNS- DYOR], is just another failure for this Co . . . . I say:- "Get on with something that makes a profit . . . . and leave cutting-edge research to the professionsals . . . selling doggy-cream wasn't your bag either, so make it something easy, eh?"

ooops! "Analyst Paul Cuddon at Peel Hunt said the result was a conclusive failure for Phytopharm's key asset, and he attributed no value to the group's remaining pipeline of drugs."

one for the dustbin

Yes looks that way!

Strategic Review Update

Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm", the "Group" or the "Company") today announces an update on the on-going strategic review which was initiated following the announcement of headline results from its Phase II clinical trial of Cogane™ in Parkinson's disease. The update will also be provided to shareholders attending the Company's AGM today.

On the 18th February Phytopharm announced that analysis of the headline results from its Phase II clinical trial of Cogane™ in Parkinson's disease indicated that the drug had not demonstrated clinically meaningful efficacy. A full analysis of the complete dataset has now been completed which confirms the initial view that no efficacy was demonstrated in the primary or secondary endpoints measured in the study.

As a result of these findings no further research and development expenditure will be committed and a staff reduction and cost saving programme has been initiated.
After discussions with major shareholders the Board has initiated a review of the strategic options available to the Company which includes the review of a number of merger and acquisition opportunities. Exploratory discussions have been held with a number of parties and further updates will be made as appropriate.

Re: Suspension of Trading


On the 18th February 2013 Phytopharm announced that analysis of the headline results from its Phase II clinical trial of Cogane™ in Parkinson's disease indicated that the drug had not demonstrated clinically meaningful efficacy. After discussions with the Company's major shareholder the Board initiated a review of the strategic options available to the Company, including a review of a number of merger and acquisition opportunities. Further to this, the Board of Phytopharm is pleased to announce that Phytopharm has recently signed heads of terms in connection with the possible acquisition of a revenue generating UK based private company in the healthcare sector ("Target").



The transaction would be structured by way of an acquisition of the Target by Phytopharm in consideration for the issue of new Phytopharm shares to the shareholders of the Target. Due to its size in relation to Phytopharm, the proposed acquisition of the Target constitutes a "reverse takeover" for the purposes of the Listing Rules. At the request of the Company, trading in Phytopharm's Premium listed shares on the Main Market of the London Stock Exchange ("Main Market") has been suspended by the UK Listing Authority pending publication of the required shareholder documents. Shareholder approval would be required to approve the acquisition of the Target which would be sought at a general meeting to be convened in due course, after which the Company also expects to delist from the Main Market and seek admission of the enlarged share capital to trading on AIM.



The Board expects to make a further announcement in due course.

Interim Results

Financial summary

· No further research and development expenditure has been committed and a staff reduction programme has been put in place.

· Loss after tax of £2.65 million (HY 2012: £4.88 million).

· Cash and money market investments of £6.33 million (HY 2012: £13.33 million; FY 2012: £8.89 million).

Yes, but what of the Co Ann of 21 May 2013? (Post No 84)- Does this say that PYM is being taken over? . . .not how I read it "Target" seems to be the other way, ie PYM is taking over a larger company - Eh?
...I could just wait and see...

From the link in post 85 :-

"On the 18 February 2013 Phytopharm announced that analysis of the headline results from its Phase II clinical trial of Cogane™ in Parkinson's disease indicated that the drug had not demonstrated clinically meaningful efficacy. After discussions with the Company's major shareholder the Board initiated a review of the strategic options available to the Company, including a review of a number of merger and acquisition opportunities. Further to this, the Board of Phytopharm is pleased to announce that Phytopharm has recently signed heads of terms in connection with the possible acquisition of a revenue generating UK based private company in the healthcare sector ("Target").

The transaction would be structured by way of an acquisition of the Target by Phytopharm in consideration for the issue of new Phytopharm shares to the shareholders of the Target. Due to its size in relation to Phytopharm, the proposed acquisition of the Target constitutes a "reverse takeover" for the purposes of the Listing Rules. At the request of the Company, trading in Phytopharm's Premium listed shares on the Main Market of the London Stock Exchange ("Main Market") was suspended on 21 May 2013 by the UK Listing Authority pending publication of the required shareholder documents. Shareholder approval would be required to approve the acquisition of the Target which would be sought at a general meeting to be convened in due course, after which the Company also expects to delist from the Main Market and seek admission of the enlarged share capital to trading on AIM. The Company expects to make a further announcement in due course."

Of course, this is the reward investors can expect having invested in the exciting tech placed in the Public Domain by the Company . . . the shares in ISA/and PEP before) being considered unworthy.
Well thanks PYM; it's good to know the Directors have retained their seats and continue to enjoy a good life, pension and happy meals.
"Rot in . . ." springs to mind.


Tech carries risk, but it should be shared by all - and I don't see why they need to delist from the main market, other than to boost a notional improvement from their new start. Snag is they still have the same dreary captains at the Helm, each pulling in different directions, no doubt.

Proposed acquisition of IXICO Limited
Proposed Issue of up to 8,479,753 New Ordinary Shares in the Company
Proposed change of name to IXICO plc
Admission of the Enlarged Issued Share Capital to trading on AIM
Renewal of Shareholder Authorities
and
Notice of General Meeting

Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm", or the "Company") today announces that terms have been agreed for the conditional acquisition (the "Acquisition") of IXICO Limited ("IXICO"), a medical technology and diagnostics company. The aggregate consideration for the Acquisition is to be satisfied by the initial issue of 8,014,403 New Ordinary Shares on Admission and the proposed issue of 465,350 New Ordinary Shares as a result of the outstanding share options under the IXICO unapproved share option share scheme. Based on the Phytopharm closing share price of 20 May 2013 immediately prior to its suspension, the aggregate consideration is valued at approximately £5.6 million.

Following completion, it is expected that Phytopharm shareholders will own approximately 45 per cent and that IXICO shareholders will own approximately 55 per cent of the Fully Diluted Enlarged Issued Share Capital. In view of the size of IXICO in relation to the Company, the Acquisition is classified as a reverse takeover under the AIM Rules and is therefore conditional, inter alia, on the approval of Shareholders in a general meeting. A copy of the admission document along with the notice of General Meeting is being sent out to shareholders shortly and will be available on the Company's website www.phytopharm.com.

The Directors of Phytopharm consider that IXICO will provide a platform from which to create value for Shareholders and will provide a different risk profile to the Company's business model. Upon completion of the Acquisition, Phytopharm plc will change its name to IXICO plc with the new ticker "IXI".